ENTA vs. RAPT, HOWL, VNDA, EPIX, NBTX, INZY, AKBA, RENB, CTNM, and VRCA
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include RAPT Therapeutics (RAPT), Werewolf Therapeutics (HOWL), Vanda Pharmaceuticals (VNDA), ESSA Pharma (EPIX), Nanobiotix (NBTX), Inozyme Pharma (INZY), Akebia Therapeutics (AKBA), Renovaro (RENB), Contineum Therapeutics (CTNM), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical preparations" industry.
RAPT Therapeutics (NASDAQ:RAPT) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.
RAPT Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
In the previous week, RAPT Therapeutics' average media sentiment score of 1.02 beat Enanta Pharmaceuticals' score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.
99.1% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 6.6% of RAPT Therapeutics shares are owned by company insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
RAPT Therapeutics has a net margin of 0.00% compared to RAPT Therapeutics' net margin of -187.77%. RAPT Therapeutics' return on equity of -60.38% beat Enanta Pharmaceuticals' return on equity.
Enanta Pharmaceuticals received 220 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. However, 67.69% of users gave RAPT Therapeutics an outperform vote while only 56.41% of users gave Enanta Pharmaceuticals an outperform vote.
RAPT Therapeutics currently has a consensus target price of $25.67, indicating a potential upside of 216.87%. Enanta Pharmaceuticals has a consensus target price of $19.33, indicating a potential upside of 56.29%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe RAPT Therapeutics is more favorable than Enanta Pharmaceuticals.
RAPT Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
RAPT Therapeutics beats Enanta Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
